Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I

Horm Res. 1994;41 Suppl 2:93-6. doi: 10.1159/000183967.

Abstract

The Diabetes Control and Complications Trial has emphasized the need for improved control of blood glucose as a means to diminish long-term complications of diabetes. LysPro-insulin is an analog of human insulin whose design was modeled on structural homology with insulin-like growth factor I. An analysis of the structural conformation of insulin suggested that an inversion of amino acids B28 and B29 in the C-terminus of the B chain could yield an insulin analog with a faster onset of biological action. This insulin analog has proved to be virtually identical to human insulin in action, with one important exception. LysPro-insulin has demonstrated an improved time course of action in control of a mealtime glucose elevation. This offers the opportunity for improved convenience and safety for patients with insulin-dependent diabetes mellitus.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Drug Design
  • Humans
  • Insulin / analogs & derivatives*
  • Insulin / chemistry
  • Insulin / pharmacokinetics*
  • Insulin-Like Growth Factor I / chemistry*
  • Molecular Sequence Data
  • Protein Multimerization
  • Sequence Homology, Amino Acid

Substances

  • Insulin
  • Insulin-Like Growth Factor I